Ozawade: Uses, Dosage & Side Effects
A histamine H3 receptor antagonist that improves wakefulness in adults with excessive daytime sleepiness due to obstructive sleep apnea
Ozawade (pitolisant) is a prescription oral medicine used to improve wakefulness and reduce excessive daytime sleepiness (EDS) in adults with obstructive sleep apnea (OSA). It belongs to a unique class of wake-promoting agents that work by blocking histamine H3 receptors in the brain, thereby increasing the release of histamine and other arousal-promoting neurotransmitters. Ozawade is intended specifically for residual sleepiness that persists despite adequate primary OSA treatment such as continuous positive airway pressure (CPAP), or for patients who cannot tolerate primary therapy. It is taken once daily in the morning, titrated slowly over several weeks, and does not directly stimulate dopamine pathways — giving it a low potential for abuse compared with classical psychostimulants.
Quick Facts: Ozawade
Key Takeaways
- Ozawade (pitolisant) is approved for adults with obstructive sleep apnea who continue to experience excessive daytime sleepiness despite primary therapy such as CPAP, or who cannot tolerate primary therapy.
- It is the first and only histamine H3 receptor antagonist/inverse agonist licensed for this indication, working by enhancing brain histamine release rather than by stimulating dopamine pathways.
- Treatment starts at 4.5 mg once daily in the morning and is titrated weekly over 3 weeks up to a maximum of 18 mg, based on individual response and tolerability.
- Pitolisant significantly reduces hormonal contraceptive efficacy — women of childbearing potential must use a reliable non-hormonal contraceptive method during treatment and for 21 days after stopping.
- Ozawade does not treat the underlying sleep apnea; CPAP or alternative airway therapy must be continued. The most common side effects are insomnia, headache, nausea, and anxiety, which often improve with continued use.
What Is Ozawade and What Is It Used For?
Ozawade contains the active substance pitolisant (as pitolisant hydrochloride), a first-in-class wake-promoting agent that targets the histamine H3 receptor. Unlike traditional psychostimulants such as amphetamine or methylphenidate, pitolisant does not directly stimulate the dopaminergic reward system. Instead, it enhances the brain’s own wake-promoting signalling by blocking presynaptic H3 autoreceptors, the “dimmer switches” on histaminergic neurons in the tuberomammillary nucleus of the posterior hypothalamus. With these brakes released, histamine release into the cortex increases, and the firing of secondary wake-promoting systems (acetylcholine, dopamine, noradrenaline) is also enhanced.
Ozawade is approved for the improvement of wakefulness and the reduction of excessive daytime sleepiness (EDS) in adults with obstructive sleep apnea (OSA) whose EDS has not been satisfactorily treated by primary OSA therapy — most commonly continuous positive airway pressure (CPAP) — or who are not tolerant to primary OSA therapy. It is essential to understand that Ozawade does not treat the airway obstruction itself: it does not open the airway, reduce snoring, lower the apnea-hypopnea index (AHI), or eliminate nocturnal hypoxia. Its role is purely symptomatic, addressing the residual cognitive and motor impairment caused by chronically fragmented sleep.
Excessive daytime sleepiness is one of the most disabling symptoms of OSA. Even when CPAP is used effectively, around 9–22% of patients continue to suffer from clinically significant residual sleepiness. Mechanisms include incomplete reversal of sleep fragmentation, persistent intermittent hypoxia-induced injury to wake-promoting neurons, comorbid sleep disorders, depression, lifestyle factors, and inadequate sleep duration. Untreated EDS impairs occupational performance, increases the risk of motor vehicle and workplace accidents, worsens mood, and reduces overall quality of life. Patients describe a constant struggle to stay awake during meetings, while reading, while driving, and even during conversations.
Ozawade was evaluated in the pivotal phase III HAROSA I and HAROSA II randomized, double-blind, placebo-controlled clinical trials. HAROSA I enrolled adults with moderate to severe OSA who were treated and adherent to CPAP but still suffered from EDS. HAROSA II enrolled adults with OSA who refused or could not tolerate CPAP. Both studies demonstrated that pitolisant significantly improved wakefulness compared with placebo, as measured by the Epworth Sleepiness Scale (ESS), and reduced subjective sleepiness without compromising nighttime sleep architecture or CPAP adherence. Improvements in functional outcomes such as the Pichot Fatigue Scale and quality of life measures were also observed.
Ozawade was first authorised by the European Medicines Agency (EMA) in November 2021 and is marketed by Bioprojet Pharma. The same active substance, pitolisant, has also been licensed under the brand name Wakix for the treatment of adult and paediatric narcolepsy with or without cataplexy. Although the molecule is identical, the indications, dose titration schedules, and patient populations are distinct, and the two brands are not interchangeable. Pitolisant is recognised in the European Sleep Research Society (ESRS) and American Academy of Sleep Medicine (AASM) clinical guidelines as a treatment option for residual EDS in OSA.
Most wake-promoting medications (modafinil, amphetamines, methylphenidate) act on dopamine and noradrenaline transporters. Pitolisant takes a fundamentally different approach by enhancing histamine signalling, which is the brain’s primary wakefulness neurotransmitter. Because it does not directly increase dopamine in the nucleus accumbens, pitolisant has demonstrated low abuse potential in human studies and is not classified as a controlled substance in most jurisdictions, which simplifies prescribing and dispensing.
What Should You Know Before Taking Ozawade?
Contraindications
Do not take Ozawade if any of the following apply to you:
- Hypersensitivity: You are allergic to pitolisant or any of the other ingredients of the tablet (listed under What Does Ozawade Contain?). Signs of allergy can include skin rash, swelling of the face or throat, and difficulty breathing.
- Severe hepatic impairment: You have serious problems with your liver (severe hepatic impairment, Child-Pugh class C). Pitolisant is extensively metabolised by the liver, and severely impaired hepatic function can lead to dangerously high blood levels of the drug and metabolites.
- Breastfeeding: You are breastfeeding. Animal studies have shown that pitolisant is excreted in milk, and a risk to the infant cannot be excluded.
Warnings and Precautions
Talk to your doctor or pharmacist before taking Ozawade if any of the following apply to you, because dose adjustment, additional monitoring, or careful risk-benefit assessment may be needed.
Pitolisant has been associated with a small, dose-dependent prolongation of the QT interval on the electrocardiogram (ECG) at supratherapeutic doses. Although clinically significant arrhythmias have not been reported in clinical trials at recommended doses, caution is required in patients with known QT prolongation, congenital long QT syndrome, severe bradycardia, recent myocardial infarction, severe hypertension, decompensated heart failure, or in those taking other QT-prolonging medicinal products (e.g., certain antiarrhythmics, antipsychotics, macrolide antibiotics). Monitor electrolytes (potassium, magnesium) before and during treatment.
- Liver disease: If you have moderate hepatic impairment (Child-Pugh class B), the maximum daily dose of Ozawade is reduced to 9 mg. Mild hepatic impairment does not require dose adjustment.
- Kidney disease: If you have moderate to severe kidney impairment, the maximum daily dose is reduced to 9 mg. Ozawade has not been studied in patients with end-stage kidney disease (creatinine clearance < 15 mL/min) and should be avoided in this population.
- Psychiatric history: Anxiety, depression, insomnia, irritability, agitation, abnormal dreams, and rarely suicidal ideation have been reported. Inform your doctor of any history of mental health conditions, and report any new or worsening mood symptoms during treatment.
- Severe obesity or anorexia: Pitolisant has been associated with weight changes (both gain and loss) in some patients. Monitoring body weight is advised in patients at extremes of body mass index.
- Epilepsy: Although a clear causal relationship has not been established, convulsions have been reported very rarely with pitolisant. Use with caution in patients with severe or uncontrolled epilepsy.
- Active gastric or duodenal ulcers: Histaminergic stimulation may theoretically increase gastric acid secretion. Caution is advised in patients with active peptic ulcer disease or those taking gastric irritants.
- Lactose intolerance: Ozawade tablets contain lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medicine.
Children and Adolescents
Ozawade is not recommended for children and adolescents below 18 years of age. The safety and efficacy of pitolisant in OSA-related EDS have not been established in this age group, and OSA in children typically requires evaluation for adenotonsillectomy, weight management, and other paediatric-specific approaches before considering pharmacological symptom management.
Pregnancy, Contraception and Breastfeeding
Pitolisant induces the liver enzyme CYP3A4 and substantially reduces the effectiveness of all hormonal contraceptive methods, including combined oral contraceptive pills, progesterone-only pills, contraceptive patches, vaginal rings, hormonal implants, and hormonal intrauterine systems. Women of childbearing potential must use an alternative reliable non-hormonal method of contraception (for example, a copper intrauterine device or barrier method) during treatment and for at least 21 days after stopping Ozawade.
Ozawade should not be used during pregnancy unless clearly necessary. Animal studies have shown reproductive toxicity, including foetal malformations at high doses. Limited human data are available; the safe use of pitolisant in pregnancy has not been established. If pregnancy occurs during treatment, contact your doctor immediately to weigh the risks and benefits of continued therapy.
Pitolisant and its metabolites are excreted in animal milk, and a risk to the breastfed infant cannot be excluded. Ozawade must not be used during breastfeeding. If wakefulness therapy is essential, breastfeeding should be discontinued.
Driving and Operating Machinery
Patients with excessive daytime sleepiness, including those receiving Ozawade, should be advised that they may be at increased risk of accidents while driving or operating machinery. Although Ozawade is intended to improve wakefulness, the underlying disorder (OSA) and individual response to treatment vary considerably. You should refrain from driving and other potentially hazardous activities until your level of wakefulness has been re-assessed and is sufficient to perform such activities safely. Discuss driving with your doctor as part of regular treatment review, and follow national regulations regarding driving with sleep disorders.
Elderly Patients
Limited data are available in patients aged 75 years and older. Pitolisant should be used with caution in elderly patients, considering possible decreased hepatic, renal, or cardiac function, and the greater frequency of concomitant disease and medication.
How Does Ozawade Interact with Other Drugs?
Pitolisant is metabolised primarily by cytochrome P450 enzymes (CYP2D6 and CYP3A4) and itself acts as an inducer of CYP3A4. This means that Ozawade can both be affected by other medications and can change how other medications work in your body. Always tell your doctor or pharmacist about all medicines you are taking, have recently taken, or might take, including over-the-counter products and herbal supplements.
Major Interactions
| Interacting Drug / Class | Mechanism | Clinical Recommendation |
|---|---|---|
| Hormonal contraceptives (oral pill, patch, ring, implant, hormonal IUD) | CYP3A4 induction by pitolisant reduces contraceptive hormone levels | Use a reliable non-hormonal contraceptive method during treatment and for 21 days after stopping |
| Strong CYP2D6 inhibitors (paroxetine, fluoxetine, quinidine, bupropion, terbinafine) | Increased plasma concentrations of pitolisant (up to 2.5-fold) | Halve the daily dose of Ozawade. Monitor for adverse effects |
| CYP3A4 inducers (rifampicin, carbamazepine, phenytoin, phenobarbital, St John’s wort) | Decreased plasma concentrations of pitolisant; loss of efficacy | Avoid combination if possible; otherwise close clinical monitoring |
| QT-prolonging medicinal products (amiodarone, sotalol, haloperidol, ziprasidone, erythromycin, moxifloxacin) | Additive QT-interval prolongation, risk of arrhythmia | Avoid combination or perform careful ECG and electrolyte monitoring |
| H1 antihistamines that cross the blood-brain barrier (diphenhydramine, chlorphenamine, hydroxyzine, promethazine, mepyramine) | Pharmacological antagonism of histaminergic wake-promoting effect | Avoid concomitant use; prefer non-sedating second-generation antihistamines |
| BCRP and OCT1 substrates (metformin, certain statins) | Pitolisant inhibits transporter activity; increased exposure of substrate | Monitor for substrate-related adverse effects; consider dose adjustment |
Other Interactions to Consider
| Drug / Class | Effect | Recommendation |
|---|---|---|
| Tricyclic antidepressants (amitriptyline, clomipramine, imipramine) | Possible reduction of pitolisant efficacy through anti-H1 activity | Monitor wakefulness response; consider alternative antidepressant if available |
| Mirtazapine | H1 antagonism may reduce wake-promoting effect | Caution; monitor effectiveness |
| Modafinil | CYP3A4 induction; potential for combined wake-promoting effect | Concomitant use is not generally recommended without specialist supervision |
| Alcohol | No direct interaction documented, but alcohol fragments sleep and worsens OSA | Limit alcohol consumption; avoid in the evening |
| Caffeine | May potentiate insomnia and tachycardia side effects | Avoid caffeine in the afternoon and evening |
This list is not exhaustive. Pharmacological interactions can be complex, particularly in patients on multiple medications. Always consult your doctor or pharmacist before starting, stopping, or changing the dose of any other medication while you are taking Ozawade, and carry an up-to-date list of your medications to all medical appointments.
The interaction between pitolisant and hormonal contraception is the most clinically important and frequently overlooked interaction with Ozawade. Patients have become pregnant while taking Ozawade and continuing oral contraceptive pills. Ensure your doctor and pharmacist explicitly discuss this with you, and that you have a documented plan for non-hormonal contraception before starting treatment. The interaction persists for at least 21 days after the last dose because of pitolisant’s long half-life and lingering CYP3A4 induction.
What Is the Correct Dosage of Ozawade?
Always take Ozawade exactly as your doctor has told you. The dose is individualised, with the lowest effective dose used to minimise side effects. The tablets are swallowed whole with a glass of water in the morning at breakfast. Taking the dose later in the day may trigger or worsen insomnia. Doubling the dose to compensate for a missed dose is never appropriate.
Adults — Standard Titration
The recommended titration schedule for adult patients with normal hepatic and renal function is gradual, allowing tolerance to develop and side effects to be detected early.
| Week | Daily Dose | Tablet(s) | Action |
|---|---|---|---|
| Week 1 | 4.5 mg once daily | 1 × 4.5 mg tablet | Starting dose |
| Week 2 | 9 mg once daily | 2 × 4.5 mg tablets | Increase if tolerated |
| Week 3 onwards | Up to 18 mg once daily | 1 × 18 mg tablet | Maintenance dose, individualised by response |
The lowest effective daily dose should be used. After the first 3 weeks the dose may be either maintained, reduced, or interrupted depending on individual response and tolerability. Treatment effectiveness is typically assessed after 4–8 weeks. If no clinically meaningful improvement in EDS has occurred at the maximum tolerated dose, discontinuation should be considered. There is no need to taper the dose when stopping Ozawade because no withdrawal syndrome has been observed.
Special Population: Moderate Hepatic Impairment (Child-Pugh B)
Start with 4.5 mg once daily. After 2 weeks, the dose can be increased to a maximum of 9 mg per day. Doses above 9 mg are not recommended. Severe hepatic impairment (Child-Pugh C) is a contraindication.
Special Population: Renal Impairment
For patients with moderate to severe renal impairment (creatinine clearance 15–59 mL/min), the maximum daily dose is 9 mg. Ozawade has not been studied in end-stage renal disease (CrCl < 15 mL/min) and is not recommended.
Special Population: Strong CYP2D6 Inhibitor Co-administration
When Ozawade is co-administered with a strong CYP2D6 inhibitor (e.g., paroxetine, fluoxetine, quinidine), the dose should be halved (e.g., maximum 9 mg per day instead of 18 mg). Titration should still proceed gradually.
Special Population: CYP2D6 Poor Metabolisers
Approximately 7–10% of people of European ancestry are CYP2D6 poor metabolisers and may experience higher pitolisant exposure. Genotyping is not routinely required, but slower titration with closer monitoring for adverse effects is appropriate when poor metaboliser status is known.
Children and Adolescents
Ozawade is not recommended for use in patients under 18 years of age. Safety and efficacy have not been established in this population for the OSA-related EDS indication.
Elderly Patients
No specific dose adjustment is required based on age alone, but pitolisant should be used with caution in patients aged 75 years and older because of limited data and the increased likelihood of impaired hepatic, renal, or cardiac function in this group. Lower starting doses and slower titration may be appropriate.
How to Take Ozawade
- Time of day: Take the entire daily dose once in the morning, at breakfast. Taking the dose later in the day increases the risk of insomnia.
- With or without food: Ozawade can be taken with or without food. Taking it with breakfast is preferred for routine and tolerability.
- Swallow whole: Swallow the tablet whole with a glass of water. Do not crush, chew, split, or dissolve the tablets.
- Continue your primary OSA treatment: Ozawade does not replace CPAP, mandibular advancement devices, positional therapy, or other primary therapies. These must be continued.
If You Forget to Take Ozawade
If you forget to take a dose in the morning, do not take it later in the day, as this can cause insomnia. Skip the missed dose and take the next dose as scheduled the following morning. Do not take a double dose to make up for a forgotten one. If you have any questions about your dosing schedule, contact your doctor or pharmacist.
If You Take More Than You Should (Overdose)
If you have taken more Ozawade than prescribed, contact a doctor, hospital emergency department, or poison control centre immediately. Symptoms of overdose may include severe headache, nausea, vomiting, abdominal pain, agitation, increased heart rate, abnormal heart rhythm, and confusion. There is no specific antidote for pitolisant overdose. Treatment is supportive, with monitoring of vital signs, ECG, and clinical status. Activated charcoal may be considered within 1 hour of ingestion in alert patients.
If You Stop Taking Ozawade
Pitolisant does not cause physical dependence and can be stopped without tapering. However, if you discontinue Ozawade, the underlying excessive daytime sleepiness will return within a few days. Do not stop treatment without first discussing it with your doctor, especially if you drive or operate machinery, so that an appropriate plan is in place.
What Are the Side Effects of Ozawade?
Like all medicines, Ozawade can cause side effects, although not everybody gets them. Most adverse reactions reported in clinical trials were mild to moderate and occurred within the first weeks of treatment, often improving as the body adapted. The frequencies below are derived from the pivotal HAROSA studies and post-marketing safety data, and are categorised according to the standard convention used in European product information.
Very Common
May affect more than 1 in 10 people
- Insomnia (difficulty falling asleep or maintaining sleep)
- Headache
Common
May affect up to 1 in 10 people
- Anxiety, nervousness
- Irritability
- Dizziness, vertigo
- Nausea, vomiting, abdominal discomfort
- Diarrhoea or constipation
- Dry mouth
- Decreased appetite
- Increased heart rate (palpitations)
- Tinnitus (ringing in the ears)
- Fatigue
- Abnormal dreams or sleep disturbance
Uncommon
May affect up to 1 in 100 people
- Depression, mood swings, agitation
- Tremor, paraesthesia (tingling sensation)
- Hot flushes, hypertension or hypotension
- Dyspnoea (shortness of breath)
- Pruritus (itching), rash, hyperhidrosis (excessive sweating)
- Muscle pain, joint pain, neck pain
- Weight changes (increased or decreased)
- Abnormal liver function tests
- QT-interval prolongation on ECG
- Restless legs symptoms
Rare
May affect up to 1 in 1,000 people
- Hallucinations (visual or auditory)
- Suicidal ideation
- Convulsions
- Severe skin reactions including angioedema
Frequency Not Known
Cannot be estimated from the available data
- Severe hypersensitivity reactions
- Cardiac arrhythmia (rare reports in post-marketing surveillance)
Insomnia is the most frequently reported side effect of Ozawade and the leading reason for treatment discontinuation. It typically occurs within the first 2–3 weeks of treatment and reflects the wake-promoting mechanism of action. Strategies that help include taking the dose as early in the morning as possible, avoiding caffeine after midday, maintaining a strict sleep-wake schedule, restricting evening alcohol, and ensuring continued use of CPAP. If insomnia persists despite these measures, dose reduction may be necessary.
Headache is also very common, especially during titration. It is usually mild and self-limiting. Adequate hydration and over-the-counter analgesics (paracetamol or ibuprofen) are usually sufficient; persistent or severe headaches should be reported to your doctor.
Psychiatric effects — including anxiety, irritability, mood changes, and rarely depression or suicidal thoughts — warrant active monitoring. Patients with a history of psychiatric illness should be identified before starting therapy, and any new or worsening mood symptoms during treatment should be reported promptly. Family members or caregivers can play an important role in recognising behavioural changes.
Cardiovascular effects are uncommon at therapeutic doses. Mild increases in heart rate and small QT-interval prolongations have been observed. Patients with structural heart disease, conduction abnormalities, or those on QT-prolonging medications should have a baseline ECG and regular monitoring as clinically indicated. Sudden onset of chest pain, palpitations, fainting, or shortness of breath warrants urgent medical assessment.
Stop Ozawade and seek immediate medical care if you develop signs of a serious allergic reaction (swelling of the face, lips, tongue, or throat; difficulty breathing; widespread severe rash), chest pain or palpitations associated with dizziness or fainting, a seizure, or new thoughts of self-harm. Less urgent but important reasons to contact your doctor include persistent or severe insomnia, mood changes lasting more than a few days, significant weight loss or gain, and any unexplained symptoms.
Reporting Side Effects
If you experience any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed here. You can also report side effects directly through your national pharmacovigilance system — for example the EMA EudraVigilance system in the EU, the MHRA Yellow Card scheme in the UK, or the FDA MedWatch program in the US. By reporting side effects, you help provide more information on the long-term safety of this medicine.
How Should You Store Ozawade?
Proper storage of Ozawade is straightforward but important to maintain the quality, safety, and efficacy of the medicine throughout its shelf life. Follow the storage instructions on the carton and the blister, and use the medicine within its labelled expiry period.
- Temperature: No special temperature requirements. Store at typical room temperature, away from direct heat sources such as radiators, ovens, and direct sunlight.
- Moisture: Keep the tablets in the original blister inside the outer carton to protect them from moisture and light. Do not transfer the tablets to other containers (such as pill organisers) for long-term storage, as this can compromise tablet stability.
- Out of reach of children: Always store medicines in a safe place where children cannot see or reach them. Even a small number of tablets can be harmful to a child.
- Expiry date: Do not use Ozawade after the expiry date printed on the carton and blister after “EXP.” The expiry date refers to the last day of that month.
- Inspection: Before each use, check that the blister is intact and the tablets are not broken, discoloured, or damaged. Damaged or discoloured tablets must not be used.
- Travel: When travelling, keep Ozawade in its original packaging and in a temperature-stable location. Avoid leaving the medicine in a hot car or direct sunlight for prolonged periods.
- Disposal: Do not throw away medicines via wastewater or household waste. Return any unused medicine to your pharmacy. These measures help protect the environment.
What Does Ozawade Contain?
Knowing what your medicine contains is important if you have allergies, intolerances (especially to lactose), or follow a specific dietary requirement. The detailed composition of Ozawade is summarised below.
Active Substance
The active substance is pitolisant, present as pitolisant hydrochloride. Each 4.5 mg film-coated tablet contains pitolisant hydrochloride equivalent to 4.45 mg of pitolisant. Each 18 mg film-coated tablet contains pitolisant hydrochloride equivalent to 17.8 mg of pitolisant. (For practical purposes, the labelled strengths of 4.5 mg and 18 mg refer to the salt; the small difference in free-base content is clinically negligible.)
Other Ingredients (Excipients)
| Ingredient | Role | Notes |
|---|---|---|
| Pitolisant hydrochloride | Active substance (H3 receptor antagonist/inverse agonist) | 4.5 mg or 18 mg per tablet |
| Microcrystalline cellulose | Diluent / filler | Provides tablet bulk |
| Croscarmellose sodium | Disintegrant | Helps tablet dissolve in the stomach |
| Talc | Glidant / lubricant | Improves powder flow during manufacturing |
| Magnesium stearate | Lubricant | Prevents sticking during compression |
| Colloidal anhydrous silica | Glidant | Improves powder flow |
| Lactose monohydrate | Diluent | Patients with lactose intolerance should consult their doctor |
| Hypromellose | Film-coating polymer | Improves swallowing and stability |
| Titanium dioxide (E171) | Coating opacifier | Provides white tablet appearance |
| Macrogol 3000 | Plasticiser | Component of film-coating |
Appearance and Pack Sizes
Ozawade tablets are white, film-coated tablets. The 4.5 mg tablet is round, and the 18 mg tablet is oblong, with one face engraved with the strength code. Tablets are supplied in PVC/PVDC/aluminium blister packs in cartons of 30 or 90 film-coated tablets. Not all pack sizes may be marketed in every country.
Marketing Authorisation Holder and Manufacturer
Ozawade is developed and marketed by Bioprojet Pharma (Paris, France), the same company that markets pitolisant under the brand name Wakix for narcolepsy. The marketing authorisation in the European Union was granted on 12 November 2021 (EU/1/21/1586). Manufacturing is performed at authorised European facilities under European Good Manufacturing Practice (GMP) standards.
Frequently Asked Questions About Ozawade
Ozawade (pitolisant) is a prescription medication that improves wakefulness and reduces excessive daytime sleepiness in adults with obstructive sleep apnea (OSA). It is intended for patients whose sleepiness has not been adequately controlled by primary OSA therapy such as continuous positive airway pressure (CPAP), or for those who cannot tolerate CPAP. It does not treat the underlying airway obstruction, so primary OSA therapy must be continued.
Most wake-promoting medications (modafinil, amphetamines, methylphenidate) act on dopamine and noradrenaline transporters. Ozawade is the first authorised wake-promoting agent that works through the histamine H3 receptor — it blocks H3 autoreceptors to enhance histamine release in the brain. Because it does not directly increase dopamine in the reward system, it has very low abuse potential and is not classified as a controlled substance in most countries, which simplifies prescribing and dispensing.
No. Ozawade only treats the symptom of daytime sleepiness; it does not open the airway, prevent apneas, or correct the nocturnal hypoxia and sleep fragmentation caused by OSA. Stopping CPAP while taking Ozawade leaves the underlying disease untreated and exposes you to long-term cardiovascular, metabolic, and neurocognitive risks. CPAP or another primary OSA therapy must be continued for the duration of pitolisant treatment.
Some patients notice improvement within the first few days, but the full therapeutic benefit typically develops over 4 to 8 weeks of dose titration. The standard schedule is 4.5 mg once daily for week 1, 9 mg for week 2, and up to 18 mg from week 3 onwards. Effectiveness is usually re-assessed after 4 to 8 weeks using validated tools such as the Epworth Sleepiness Scale and Maintenance of Wakefulness Test, in combination with the patient’s own report of functional improvement.
No. Pitolisant induces the liver enzyme CYP3A4 and substantially reduces the effectiveness of all hormonal contraceptives, including the combined pill, progesterone-only pill, patches, vaginal rings, hormonal implants, and hormonal IUDs. Pregnancies have been reported in women using hormonal contraception while taking pitolisant. Women of childbearing potential must use a reliable non-hormonal contraceptive method (for example, a copper intrauterine device or barrier contraception) during treatment and for at least 21 days after the last dose.
Ozawade has not been associated with physical dependence, withdrawal symptoms, or addictive behaviour in clinical studies. Because it does not directly stimulate the dopamine reward pathway, its abuse potential is very low. It is not scheduled as a controlled substance in the European Union, the United Kingdom, or many other jurisdictions, in contrast to amphetamines and modafinil. This regulatory status simplifies prescribing, refills, and travel with the medication.
Insomnia is the most common side effect of Ozawade and is largely a consequence of its wake-promoting action. Strategies that usually help include taking the dose as early in the morning as possible, avoiding caffeine after lunchtime, maintaining a regular sleep-wake schedule, avoiding alcohol in the evening, ensuring consistent CPAP use, and creating a dark, quiet bedroom environment. If insomnia persists despite these measures, your doctor may reduce the dose. Sleeping tablets are usually not recommended as a long-term solution.
There is no specific pharmacological interaction between Ozawade and alcohol, but alcohol is a known relaxant of upper-airway muscles and worsens obstructive sleep apnea. It also fragments sleep and can blunt the wake-promoting effect of pitolisant the following day. The general recommendation is to limit alcohol intake, avoid alcohol in the evening, and discuss your individual situation with your doctor.
References
- European Medicines Agency (EMA). Ozawade (pitolisant) – Summary of Product Characteristics and EPAR. Last updated 2025. Available at: EMA Ozawade EPAR.
- Dauvilliers Y, Verbraecken J, Partinen M, et al. Pitolisant for Daytime Sleepiness in Patients with Obstructive Sleep Apnea Who Refuse Continuous Positive Airway Pressure Treatment. A Randomized Trial. Am J Respir Crit Care Med. 2020;201(9):1135–1145. doi:10.1164/rccm.201907-1284OC.
- Pepin JL, Georgiev O, Tiholov R, et al. Pitolisant for Residual Excessive Daytime Sleepiness in OSA Patients Adhering to CPAP: A Randomized Trial. Chest. 2021;159(4):1598–1609. doi:10.1016/j.chest.2020.09.281.
- Lin JS, Sergeeva OA, Haas HL. Histamine H3 Receptors and Sleep-Wake Regulation. J Pharmacol Exp Ther. 2011;336(1):17–23. doi:10.1124/jpet.110.170134.
- Kollb-Sielecka M, Demolis P, Emmerich J, et al. The European Medicines Agency Review of Pitolisant for Treatment of Narcolepsy: Summary of the Scientific Assessment by the Committee for Medicinal Products for Human Use. Sleep Med. 2017;33:125–129. doi:10.1016/j.sleep.2017.01.002.
- Maski K, Trotti LM, Kotagal S, et al. Treatment of Central Disorders of Hypersomnolence: An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med. 2021;17(9):1881–1893. doi:10.5664/jcsm.9328.
- Randerath W, Verbraecken J, de Raaff CAL, et al. European Respiratory Society Guideline on Non-CPAP Therapies for Obstructive Sleep Apnoea. Eur Respir Rev. 2021;30(162):210200. doi:10.1183/16000617.0200-2021.
- National Institute for Health and Care Excellence (NICE). Pitolisant for Treating Excessive Daytime Sleepiness Caused by Obstructive Sleep Apnoea. Technology Appraisal Guidance TA776. 2022.
- British National Formulary (BNF). Pitolisant. Joint Formulary Committee, BMJ Group and Pharmaceutical Press. London. 2025.
- World Health Organization (WHO). Sleep Apnoea: Global Burden and Public Health Implications. Geneva. 2024.
About Our Medical Team
All content on iMedic is created and reviewed by qualified medical professionals following international evidence-based guidelines. Our editorial process ensures accuracy, currency, and clinical relevance.
Medical Content Team
Specialists in sleep medicine, pulmonology, and clinical pharmacology with extensive experience in the diagnosis and management of obstructive sleep apnea and central disorders of hypersomnolence.
Medical Review Board
Independent panel of board-certified physicians who verify all medical claims against current evidence and international guidelines (WHO, EMA, FDA, AASM, ESRS, NICE).
Editorial Standards
All content follows the GRADE evidence framework and is based on Level 1A evidence from systematic reviews and randomized controlled trials where available.
Independence
iMedic receives no pharmaceutical company funding or sponsorship. All content is editorially independent, ensuring unbiased medical information for patients and caregivers.